2.1
Epcoritamab (Tepkinly, AbbVie) is indicated for 'adult patients with relapsed or refractory diffuse large B‑cell lymphoma (DLBCL) after two or more lines of systemic therapy'.
2 Information about epcoritamab
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for epcoritamab 4-mg/0.8 ml concentrate for solution for injection and epcoritamab 48-mg solution for injection.
Price
2.3
The list price for epcoritamab is £6,568 per 48‑mg vial and £547.33 per 4‑mg vial (excluding VAT; company submission).
2.4
The company has a commercial arrangement. This makes epcoritamab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.